Studies have shown that the first treatment you receive for cancer is by far the most important. On average, multiple myeloma patients who begin their treatment at Seattle Cancer Care Alliance (SCCA) have better survival rates than those who started treatment elsewhere.
SCCA provides superior, leading-edge treatment for people diagnosed with multiple myeloma, a form of cancer that affects white blood cells called plasma cells.
Stem cell transplants (using peripheral blood stem cells or stem cells from bone marrow) are an important treatment option for people with myeloma who are good candidates for transplant. The Fred Hutchinson Transplant program at SCCA ranked first in outcomes in a five-year study by the National Marrow Donor Program that measured one-year survival rates of patients among 122 transplant centers in the United States. For all our patients we offer many treatment options based on each person’s unique situation.
SCCA was formed, in part, to bring promising new cancer treatments to patients faster. This means that people who have multiple myeloma will find more treatment options at SCCA than might be found elsewhere. Many or our patients receive such therapies through clinical research studies conducted at SCCA and its parent organizations, Fred Hutchinson Cancer Research Center and UW Medicine. The doctors here are world leaders in research and working to better understand the causes of multiple myeloma and provide effective treatments.